The FDA declined approval for Ultragenyx Pharmaceutical on July 14, 2025, citing manufacturing concerns. Analyst comments were also made on that day.
1 report, 1 independent
Updated Jul 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA declined approval for Ultragenyx Pharmaceutical on July 14, 2025, citing manufacturing concerns. Analyst comments were also made on that day.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Ultragenyx Pharmaceutical
biopharmaceutical company based in Novato, California, United States
Nothing else this week.
Related events
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- Future sales of a product are contingent upon obtaining the necessary FDA registration and labeling, while the state simultaneously announces actions to remove regulatory barriers.
- FDA approval enables commercial opportunity involving CBRE Group.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Litigation regarding FDA approval process.
Coverage
Newest first; wire copies grouped- BioPharma DiveFDA rejects Ultragenyx gene therapy over manufacturing concerns This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive n